Versant Capital Management, Inc Eye Point Pharmaceuticals, Inc. Transaction History
Versant Capital Management, Inc
- $578 Million
- Q1 2025
A detailed history of Versant Capital Management, Inc transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Versant Capital Management, Inc holds 741 shares of EYPT stock, worth $4,720. This represents 0.0% of its overall portfolio holdings.
Number of Shares
741
Previous 492
50.61%
Holding current value
$4,720
Previous $3,000
33.33%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding EYPT
# of Institutions
158Shares Held
72.8MCall Options Held
187KPut Options Held
225K-
Cormorant Asset Management, LP Boston, MA8.33MShares$53 Million4.9% of portfolio
-
Suvretta Capital Management, LLC New York, NY6.78MShares$43.2 Million2.1% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.75MShares$36.6 Million0.08% of portfolio
-
Franklin Resources Inc San Mateo, CA4.14MShares$26.4 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.8MShares$24.2 Million0.0% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $217M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...